

Gregory Piazza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3219978/publications.pdf>

Version: 2024-02-01

140
papers

9,058
citations

66343

42
h-index

42399

92
g-index

140
all docs

140
docs citations

140
times ranked

11929
citing authors

#	ARTICLE	IF	CITATIONS
1	Right Ventricular Recovery: Early and Late Changes after Acute PE Diagnosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 797-808.	2.7	2
2	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 131-141.	3.4	55
3	Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1061-1070.	3.4	4
4	Off the beaten path: the need for innovation in medical therapy to improve outcomes in acute pulmonary embolism. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 10-12.	1.0	2
5	Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy. <i>Blood Advances</i> , 2022, 6, 2967-2976.	5.2	23
6	Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. <i>Contemporary Clinical Trials</i> , 2022, 115, 106714.	1.8	3
7	Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 766-776.	2.1	9
8	Optimal reperfusion strategy in acute high-risk pulmonary embolism requiring extracorporeal membrane oxygenation support: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2022, 60, 2102977.	6.7	11
9	Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study. <i>Thrombosis Research</i> , 2022, 214, 122-131.	1.7	3
10	Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. <i>American Heart Journal</i> , 2022, 251, 43-53.	2.7	59
11	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	6.1	15
12	Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. <i>JAMA Network Open</i> , 2022, 5, e2215580.	5.9	11
13	Patients with perceived high-bleeding risk and computerized decision support for stroke prevention in atrial fibrillation: an AF-ALERT substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 281-290.	2.1	2
14	Update on Guidelines for the Management of Cancer-Associated Thrombosis. <i>Oncologist</i> , 2021, 26, e24-e40.	3.7	76
15	Trailblazing in pulmonary embolism research: the importance of extending beyond randomized controlled trials. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 237-239.	1.0	0
16	Thrombophilia, Inflammation, and Recurrent Pregnancy Loss: A Case-Based Review. <i>Seminars in Reproductive Medicine</i> , 2021, 39, 062-068.	1.1	10
17	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1903-1921.	2.8	150
18	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1620.	7.4	515

#	ARTICLE	IF	CITATIONS
19	Stroke risk factors and outcomes among hospitalized women with atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2021, 52, 1023-1031.	2.1	1
20	Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. American Heart Journal, 2021, 235, 12-23.	2.7	36
21	An Original Risk Score to Predict Early Major Bleeding in Acute Pulmonary Embolism. Chest, 2021, 160, 1832-1843.	0.8	25
22	Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19. Journal of the American College of Cardiology, 2021, 78, 408-411.	2.8	44
23	Findings from a multicentre, observational study on reproductive outcomes in women with unexplained recurrent pregnancy loss: the OTTILIA registry. Human Reproduction, 2021, 36, 2083-2090.	0.9	17
24	Images in Vascular Medicine: Pulmonary embolism and acute aortic syndromes “Double trouble when vascular medicine emergencies meet. Vascular Medicine, 2021, , 1358863X2110296.	1.5	0
25	Impact of Atrial Fibrillation on In-Hospital Mortality and Stroke in Acute Aortic Syndromes. American Journal of Medicine, 2021, 134, 1419-1423.	1.5	2
26	Loss of Pulmonary Vascular Volume as a Predictor of Right Ventricular Dysfunction and Mortality in Acute Pulmonary Embolism. Circulation: Cardiovascular Imaging, 2021, 14, e012347.	2.6	9
27	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. Journal of Thrombosis and Haemostasis, 2021, 19, 3080-3089.	3.8	13
28	Stability of Alteplase for Catheter-Directed, Ultrasound-Facilitated Thrombolysis. Blood Advances, 2021, 5, 5283-5289.	5.2	1
29	First-in-Human Study to Assess the Safety and Feasibility of the Bashir Endovascular Catheter for the Treatment of Acute Intermediate-Risk Pulmonary Embolism. Circulation: Cardiovascular Interventions, 2021, 14, e009611.	3.9	15
30	Association of ABO blood group type with cardiovascular events in COVID-19. Journal of Thrombosis and Thrombolysis, 2021, 51, 584-586.	2.1	14
31	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. Journal of the American College of Cardiology, 2021, 78, 1635-1654.	2.8	42
32	Reply: The pathway to the “truth” in the study of recurrent pregnancy loss and thrombophilia. Human Reproduction, 2021, 37, 191-193.	0.9	0
33	Thrombophilia, Antithrombotic Therapy, and Recurrent Pregnancy Loss: A Call for Pragmatism in the Face of Unknowns. Seminars in Reproductive Medicine, 2021, 39, 167-169.	1.1	3
34	Abstract 11603: Pulmonary Artery Dilation in Submassive Acute Pulmonary Embolus and Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2021, 144, .	1.6	1
35	Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT). European Heart Journal, 2020, 41, 1086-1096.	2.2	35
36	Predictors of Not Initiating Anticoagulation After Incident Venous Thromboembolism: A Danish Nationwide Cohort Study. American Journal of Medicine, 2020, 133, 463-472.e5.	1.5	5

#	ARTICLE	IF	CITATIONS
37	The Potential Role of Coagulation Factor Xa in the Pathophysiology of COVID-19: A Role for Anticoagulants as Multimodal Therapeutic Agents. TH Open, 2020, 04, e288-e299.	1.4	23
38	A fortune teller's dream or clinician's nightmare: Right ventricular assessment for risk prediction in pulmonary embolism. Thrombosis Research, 2020, 195, 169-170.	1.7	1
39	Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 2548.	7.4	117
40	One-Year Echocardiographic, Functional, and Quality of Life Outcomes After Ultrasound-Facilitated Catheter-Based Fibrinolysis for Pulmonary Embolism. Circulation: Cardiovascular Interventions, 2020, 13, e009012.	3.9	23
41	Coagulation Status and Venous Thromboembolism Risk in African Americans: A Potential Risk Factor in COVID-19. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962094367.	1.7	26
42	Meta-Analysis Comparing Direct Oral Anticoagulants to Low Molecular Weight Heparin for Treatment of Venous Thromboembolism in Patients With Cancer. American Journal of Cardiology, 2020, 133, 175-178.	1.6	4
43	Diagnosis and Treatment of Lower Extremity Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2020, 324, 1765.	7.4	84
44	Advanced Management of Intermediate- and High-Risk Pulmonary Embolism. Journal of the American College of Cardiology, 2020, 76, 2117-2127.	2.8	48
45	Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19. Journal of the American College of Cardiology, 2020, 76, 2060-2072.	2.8	230
46	Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. American Journal of Medicine, 2020, 133, 1-27.	1.5	18
47	Development of Sex-Stratified Prediction Models for Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study. Thrombosis and Haemostasis, 2020, 120, 805-814.	3.4	13
48	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis, 2020, 120, 1004-1024.	3.4	206
49	Predictors of Treatment Response Following Ultrasound-Facilitated Catheter-Directed Thrombolysis for Submassive and Massive Pulmonary Embolism. Circulation: Cardiovascular Interventions, 2020, 13, e008747.	3.9	8
50	Running thin: implications of a heparin shortage. Lancet, The, 2020, 395, 534-536.	13.7	20
51	Listen to Your Heart (but DONâ€™T Look at Theirs): Risk Assessment for Home Treatment of Pulmonary Embolism. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 20-21.	5.6	2
52	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology, 2020, 75, 2950-2973.	2.8	2,392
53	Extended oral anticoagulation after incident venous thromboembolism â€“ a paradigm shift?. Expert Review of Cardiovascular Therapy, 2020, 18, 201-208.	1.5	3
54	Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. British Journal of Haematology, 2020, 190, 555-561.	2.5	36

#	ARTICLE	IF	CITATIONS
55	Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. Thrombosis Research, 2020, 196, 382-394.	1.7	62
56	Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. Seminars in Thrombosis and Hemostasis, 2020, 46, 908-918.	2.7	13
57	Identification and Outcomes of Hospitalized Medically Ill Patients Who Are Candidates for Extended Duration Thromboprophylaxis. TH Open, 2020, 04, e344-e350.	1.4	0
58	Collaborative Cardiology and Pulmonary Management of Pulmonary Hypertension. Chest, 2019, 156, 200-202.	0.8	3
59	Peripheral Artery Disease: Past, Present, and Future. American Journal of Medicine, 2019, 132, 1133-1141.	1.5	123
60	Thromboprophylaxis Strategies in Acute Medically Ill Patients. Current Emergency and Hospital Medicine Reports, 2019, 7, 118-126.	1.5	0
61	Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association. Circulation, 2019, 140, e774-e801.	1.6	241
62	Fine-tuning the decision to initiate anticoagulation in atrial fibrillation by accounting for age and cardiovascular comorbidities. European Heart Journal, 2019, 40, 1515-1517.	2.2	2
63	Vascular Teams in Peripheral Vascular Disease. Journal of the American College of Cardiology, 2019, 73, 2477-2486.	2.8	32
64	Anticoagulation Strategies in Patients With Cancer. Journal of the American College of Cardiology, 2019, 73, 1336-1349.	2.8	121
65	Andexanet Alfa (Andexxa) Formulary Review. Critical Pathways in Cardiology, 2019, 18, 66-71.	0.5	17
66	Quantification and Significance of Pulmonary Vascular Volume in Predicting Response to Ultrasound-Facilitated, Catheter-Directed Fibrinolysis in Acute Pulmonary Embolism (SEATTLE-3D). Circulation: Cardiovascular Imaging, 2019, 12, e009903.	2.6	13
67	Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients. Journal of Thrombosis and Thrombolysis, 2019, 47, 331-335.	2.1	3
68	A midterm report card for pulmonary embolism response teams. Vascular Medicine, 2018, 23, 72-74.	1.5	11
69	Surgical pulmonary embolectomy and catheter-directed thrombolysis for treatment of submassive pulmonary embolism. Journal of Cardiac Surgery, 2018, 33, 252-259.	0.7	18
70	Catheter-directed, ultrasound-facilitated fibrinolysis in obese patients with massive and submassive pulmonary embolism. Journal of Thrombosis and Thrombolysis, 2018, 45, 257-263.	2.1	5
71	A Review of Thrombolysis in Venous Thromboembolism With an Analysis of Alteplase Admixture Stability. Current Emergency and Hospital Medicine Reports, 2018, 6, 54-61.	1.5	3
72	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Circulation, 2018, 137, 684-692.	1.6	22

#	ARTICLE	IF	CITATIONS
73	Risk Stratification Model: Lower-Extremity Ultrasonography for Hospitalized Patients with Suspected Deep Vein Thrombosis. <i>Journal of General Internal Medicine</i> , 2018, 33, 21-25.	2.6	6
74	Oh Heavy Burden: Recognizing the Risk of Venous Thromboembolism in Women Undergoing Assisted Reproduction. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2011-2013.	3.4	9
75	Let's Stop Dichotomizing Venous Thromboembolism as Provoked or Unprovoked. <i>Circulation</i> , 2018, 138, 2591-2593.	1.6	22
76	Anticoagulation and Mortality Rates among Hospitalized Patients with Atrial Fibrillation. <i>TH Open</i> , 2018, 02, e33-e38.	1.4	7
77	Antiplatelet Prescription in Atrial Fibrillation: Association with a Low Rate of Anticoagulation. <i>TH Open</i> , 2018, 02, e229-e232.	1.4	2
78	A case of Horner's syndrome after catheter-based fibrinolysis for pulmonary embolism. <i>Vascular Medicine</i> , 2018, 23, 489-490.	1.5	0
79	Dementia and Atrial Fibrillation: Pathophysiological Mechanisms and Therapeutic Implications. <i>American Journal of Medicine</i> , 2018, 131, 1408-1417.	1.5	34
80	Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test?. <i>Vascular Medicine</i> , 2018, 23, 388-399.	1.5	24
81	A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1401-1410.	2.9	280
82	Great Debates in Vascular Medicine: Extended duration anticoagulation for unprovoked venous thromboembolism – Coming to consensus when the debate rages on. <i>Vascular Medicine</i> , 2018, 23, 384-387.	1.5	6
83	Heparin-Induced Thrombocytopenia in Healthy Individuals with Continuous Heparin Infusion. <i>TH Open</i> , 2018, 02, e49-e53.	1.4	0
84	Computed tomography angiography with pulmonary artery thrombus burden and right-to-left ventricular diameter ratio after pulmonary embolism. <i>Vascular</i> , 2017, 25, 54-62.	0.9	6
85	Risk factors for major bleeding in the SEATTLE II trial. <i>Vascular Medicine</i> , 2017, 22, 44-50.	1.5	33
86	The evidence supporting treatment of reflux and obstruction in chronic venous disease. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2017, 5, 399-412.	1.6	11
87	Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis in elderly patients with pulmonary embolism: A SEATTLE II sub-analysis. <i>Vascular Medicine</i> , 2017, 22, 324-330.	1.5	3
88	Evaluation of a Device Combining an Inferior Vena Cava Filter and a Central Venous Catheter for Preventing Pulmonary Embolism Among Critically Ill Trauma Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1248-1254.	0.5	22
89	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.	1.5	24
90	Implementation of a Comprehensive Post-Discharge Venous Thromboembolism Prophylaxis Program for Abdominal and Pelvic Surgery Patients. <i>Journal of the American College of Surgeons</i> , 2016, 223, 804-813.	0.5	21

#	ARTICLE	IF	CITATIONS
91	Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study. <i>Vascular Medicine</i> , 2016, 21, 361-368.	1.5	15
92	Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. <i>American Journal of Medicine</i> , 2016, 129, 1198-1204.	1.5	121
93	Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 68-80.	2.1	81
94	Cardiovascular Complications of Novel Multiple Myeloma Treatments. <i>Circulation</i> , 2016, 133, 908-912.	1.6	36
95	Multidisciplinary Pulmonary Embolism Response Teams. <i>Circulation</i> , 2016, 133, 98-103.	1.6	129
96	A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis. <i>Journal of Visualized Experiments</i> , 2015, , e52761.	0.3	3
97	Performance of Wells Score for Deep Vein Thrombosis in the Inpatient Setting. <i>JAMA Internal Medicine</i> , 2015, 175, 1112.	5.1	84
98	Beyond Virchow's Triad: Does cardiovascular inflammation explain the recurrent nature of venous thromboembolism?. <i>Vascular Medicine</i> , 2015, 20, 102-104.	1.5	16
99	Fat Embolism Syndrome. <i>Circulation</i> , 2015, 131, 317-320.	1.6	105
100	Surgical Embolectomy for Acute Massive and Submassive Pulmonary Embolism in a Series of 115 Patients. <i>Annals of Thoracic Surgery</i> , 2015, 100, 1245-1252.	1.3	115
101	Mesenteric Venous Thrombosis. <i>Circulation</i> , 2015, 131, 1599-1603.	1.6	56
102	Surgical Pulmonary Embolectomy. <i>Circulation</i> , 2015, 132, 1146-1151.	1.6	18
103	A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1382-1392.	2.9	648
104	Venous Thromboembolism in Patients With Prior Stroke. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 43-49.	1.7	6
105	Thrombophilia and Hypercoagulability. <i>Circulation</i> , 2014, 130, e9-10.	1.6	1
106	Warfarin Versus Novel Oral Anticoagulants. <i>Circulation</i> , 2014, 130, e191-3.	1.6	48
107	Varicose Veins. <i>Circulation</i> , 2014, 130, e59-61.	1.6	1
108	Varicose Veins. <i>Circulation</i> , 2014, 130, 582-587.	1.6	80

#	ARTICLE	IF	CITATIONS
109	Thrombophilia Testing, Recurrent Thrombosis, and Women's Health. <i>Circulation</i> , 2014, 130, 283-287.	1.6	17
110	Randomized Trial of Physician Alerts for Thromboprophylaxis after Discharge. <i>American Journal of Medicine</i> , 2013, 126, 435-442.	1.5	25
111	Submassive Pulmonary Embolism. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 171.	7.4	42
112	Venous Thromboembolism and Cancer. <i>Circulation</i> , 2013, 128, 2614-2618.	1.6	33
113	Venous Thromboembolism in Hospitalized Patients With Active Cancer. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 469-475.	1.7	16
114	Cerebral Venous Thrombosis. <i>Circulation</i> , 2012, 125, 1704-1709.	1.6	117
115	Patient Education Program for Venous Thromboembolism Prevention in Hospitalized Patients. <i>American Journal of Medicine</i> , 2012, 125, 258-264.	1.5	45
116	Venous Thromboembolism in Patients with Diabetes Mellitus. <i>American Journal of Medicine</i> , 2012, 125, 709-716.	1.5	83
117	Venous Thromboembolism in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Medicine</i> , 2012, 125, 1010-1018.	1.5	33
118	Anticoagulation-associated Adverse Drug Events. <i>American Journal of Medicine</i> , 2011, 124, 1136-1142.	1.5	92
119	Venous Thromboembolism in Heart Failure: Preventable Deaths During and After Hospitalization. <i>American Journal of Medicine</i> , 2011, 124, 252-259.	1.5	42
120	Venous thromboembolism in patients with symptomatic atherosclerosis. <i>Thrombosis and Haemostasis</i> , 2011, 106, 1095-1102.	3.4	26
121	Physician alerts to prevent venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 1-6.	2.1	15
122	Fibrinolysis for acute pulmonary embolism. <i>Vascular Medicine</i> , 2010, 15, 419-428.	1.5	61
123	Thromboangiitis Obliterans. <i>Circulation</i> , 2010, 121, 1858-1861.	1.6	146
124	A Diagnosis in Vein. <i>American Journal of Medicine</i> , 2010, 123, 701-703.	1.5	0
125	Management of Submassive Pulmonary Embolism. <i>Circulation</i> , 2010, 122, 1124-1129.	1.6	113
126	Venous Thromboembolism and Atherothrombosis An Integrated Approach. <i>Circulation</i> , 2010, 121, 2146-2150.	1.6	99

#	ARTICLE	IF	CITATIONS
127	Venous thromboembolic events in hospitalised medical patients. <i>Thrombosis and Haemostasis</i> , 2009, 102, 505-510.	3.4	57
128	Physician Alerts to Prevent Symptomatic Venous Thromboembolism in Hospitalized Patients. <i>Circulation</i> , 2009, 119, 2196-2201.	1.6	88
129	Computerized Decision Support for the Cardiovascular Clinician. <i>Circulation</i> , 2009, 120, 1133-1137.	1.6	40
130	Improving Clinical Effectiveness in Thromboprophylaxis for Hospitalized Medical Patients. <i>American Journal of Medicine</i> , 2009, 122, 230-232.	1.5	17
131	Heart Failure in Patients With Deep Vein Thrombosis. <i>American Journal of Cardiology</i> , 2008, 101, 1056-1059.	1.6	38
132	Deep-Vein Thrombosis in the Elderly. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2008, 14, 393-398.	1.7	33
133	Pulmonary Embolism in Heart Failure. <i>Circulation</i> , 2008, 118, 1598-1601.	1.6	45
134	Double Trouble for 2,609 Hospitalized Medical Patients Who Developed Deep Vein Thrombosis. <i>Chest</i> , 2007, 132, 554-561.	0.8	87
135	Acute Pulmonary Embolism. <i>Circulation</i> , 2006, 114, e42-7.	1.6	80
136	Acute Pulmonary Embolism. <i>Circulation</i> , 2006, 114, e28-32.	1.6	128
137	Venous Thromboembolism Guidebook. <i>Critical Pathways in Cardiology</i> , 2006, 5, 211-227.	0.5	5
138	An Unusual Explanation for Episodic Dyspnea. <i>Circulation</i> , 2006, 114, e485-6.	1.6	0
139	The Acutely Decompensated Right Ventricle. <i>Chest</i> , 2005, 128, 1836-1852.	0.8	197
140	Periprocedural Management of the Chronically Anticoagulated Patient. <i>Critical Pathways in Cardiology</i> , 2003, 2, 96-103.	0.5	9